Perioperative Use of Selective Serotonin Reuptake Inhibitors and Risks for Adverse Outcomes of Surgery | Depressive Disorders | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Original Investigation
June 24, 2013

Perioperative Use of Selective Serotonin Reuptake Inhibitors and Risks for Adverse Outcomes of Surgery

Author Affiliations

Author Affiliations: Division of Hospital Medicine, Department of Medicine (Dr Auerbach and Ms Maselli), and Departments of Epidemiology and Biostatistics (Dr Vittinghoff) and Psychiatry (Dr Young), University of California, San Francisco; School of Public Health and Health Sciences, University of Massachusetts, Amherst (Dr Pekow); Center for Quality of Care Research, Baystate Medical Center, Springfield, Massachusetts (Drs Pekow and Lindenauer); and Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts (Dr Lindenauer).

JAMA Intern Med. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714

Importance Single-site studies have described an association between use of selective serotonin reuptake inhibitors (SSRIs) and adverse outcomes of surgery. Multicenter studies including a broad range of surgical procedures that explore rare outcomes, such as bleeding and mortality, and that account for indications for administration of SSRIs are needed.

Objective To determine whether perioperative use of SSRIs is associated with adverse outcomes of surgery in a national sample of patients.

Design Retrospective study of patients 18 years or older who underwent major surgery from January 1, 2006, through December 31, 2008, at 375 US hospitals. We used multivariable hierarchical models to estimate associations between SSRI use and our outcomes. Pharmacy data were used to determine whether a patient received an SSRI in the perioperative period.

Setting Three hundred seventy-five US hospitals.

Participants Five hundred thirty thousand four hundred sixteen patients 18 years or older.

Exposure Perioperative use of SSRIs.

Main Outcomes and Measures In-hospital mortality, length of stay, readmission at 30 days, bleeding events, transfusions, and incidence of ventricular arrhythmias.

Results Patients receiving SSRIs were more likely to have obesity, chronic pulmonary disease, or hypothyroidism (P < .001 for each) and more likely to have depression (41.0% vs 6.2%, P < .001). After adjustment, patients receiving SSRIs had higher odds of in-hospital mortality (adjusted odds ratio, 1.20 [95% CI, 1.07-1.36]), bleeding (1.09 [1.04-1.15]), and readmission at 30 days (1.22 [1.18-1.26]). Similar results were observed in propensity-matched analyses, although the risk of inpatient mortality was attenuated among patients with depression. Sensitivity analyses suggest that, to invalidate our results, an unmeasured covariate would have to have higher prevalence and be more strongly associated with mortality than any covariate included in our models.

Conclusions and Relevance Receiving SSRIs in the perioperative period is associated with a higher risk for adverse events. Determining whether patient factors or SSRIs themselves are responsible for elevated risks requires prospective study.